# First clinical use of the kisspeptin analog TAK-683 in the treatment of a follicular cyst in a goat: case report

## TL;DR

A goat with a follicular cyst was successfully treated with TAK-683, a kisspeptin analog, showing it could be a new treatment option in veterinary medicine.

## Contribution

First clinical use of TAK-683 to treat a follicular cyst in a goat, offering a potential alternative to GnRH agonists.

## Key findings

- A single 5 µg dose of TAK-683 induced luteinization and normalized estradiol and progesterone levels.
- Color Doppler confirmed luteal development followed by natural luteolysis and follicular activity resumption.
- TAK-683 resolved the follicular cyst and normalized the goat's behavior.

## Abstract

This case report presents the therapeutic response to TAK‑683, a long-acting kisspeptin analog, in the treatment of a follicular cyst that developed following a conventional estrus synchronization protocol in a goat during the non-breeding season. A two-year-old lactating Aleppo goat showing persistent nymphomaniac behaviour after estrus synchronization was diagnosed with an ovarian follicular cyst by transrectal ultrasonography. The left ovary contained a 17.7 mm thin-walled anechoic cyst, while serum estradiol (14.5 pg/mL) was elevated and progesterone (1.6 ng/mL) was low. The goat was treated with a single subcutaneous dose of the kisspeptin analog TAK-683 (5 µg, Day 0). Therapeutic efficacy was assessed by monitoring ovarian ultrasonography and serum hormones on Days 3, 10, 13, and 17. Following treatment, the cyst underwent luteinization accompanied by a rise in progesterone (peak 6.4 ng/mL) and a decline in estradiol to basal levels, alongside normalization of behaviour. Color Doppler assessment confirmed progressive luteal development and vascularization, followed by natural luteolysis on Day 17 and resumption of follicular activity. In conclusion, this is the first clinical report demonstrating the successful use of TAK‑683 in resolving a follicular cyst in goats. These findings suggest that TAK‑683, beyond its ovulation-inducing role, may offer a promising therapeutic alternative to GnRH agonists for managing reproductive pathologies in veterinary gynaecology.

First report of follicular cyst treatment in a goat with TAK-683.

5 µg of TAK-683 induced luteinization and normalized hormone levels.

TAK-683 may offer an alternative to GnRH agonists in follicular cyst treatment.